Ossur Hf : Share buyback program completed

Reykjavík, 8 October 2018

On 6 March 2018, Össur hf. initiated a share buy-back program, see Company announcement no. 16/2018.

The purpose of the share buyback program was to reduce the Company’s share capital and adjust the capital structure by distributing capital to shareholders in line with the Company’s Capital Structure and Dividend Policy. The program would end no later than 28 February 2019. The Company could purchase up to 5,000,000 shares under the program, corresponding to 1.2% of the current share capital. The total consideration for shares purchased under the program could not exceed USD 10 million.

Össur acquired 2,130,549 shares under the program at the average price of DKK 30.05. The total consideration amounted to USD 10 million (approx. DKK 65 million) and thus the program has been completed. Össur currently holds 6,143,780 own shares, corresponding to 1.4% of the Company’s total share capital.

The share buyback program was carried out in accordance with Regulation No. 596/2014 of the European Parliament and of the Council on market abuse (“MAR”), and the Commission delegated regulation No. 2016/1052.

Contact persons:

Jón Sigurðsson, President & CEO     Tel: +354 515 1300

Sveinn Sölvason, CFO     Tel: +354 515 1300

Össur press releases by e-mail: If you wish to receive Össur press releases by e-mail please register at the following web-site: http://www.ossur.com/investormailings

About Össur Össur (NASDAQ: OSSR) is a global leader in non-invasive orthopedics that help people live a life without limitations. Its business is focused on improving people’s mobility through the delivery of innovative technologies within the fields of braces, supports and prosthetic limbs. A recognized “Technology Pioneer”, Össur invests significantly in research and product development; its award-winning designs ensuring a consistently strong position in the market. Successful patient and clinical outcomes are further empowered via Össur’s educational programs and business solutions.  Headquartered in Iceland, Össur has major operations in the Americas, Europe and Asia, with additional distributors worldwide. www.ossur.com

Forward-Looking Statement This press release includes “forward-looking statements” which involve risks and uncertainties that could cause actual results to differ materially from results expressed or implied by these statements. Össur hf. undertakes no obligation and does not intend to update these forward-looking statements to reflect events or circumstances occurring after this press release. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement.

TranS1® Announces NICE Guidance for Approval of AxiaLIF® in the UK’s National Health System (NHS)

Stryker’s Advanced Guidance Technologies announces partnerships with Synaptive Medical and Ziehm Imaging

KALAMAZOO, Michigan, USA, Oct. 8, 2018 /PRNewswire/ — Stryker’s Advanced Guidance Technologies business (formerly known as Stryker’s Navigation business) announced today it has entered into strategic partnerships with Synaptive Medical and Ziehm Imaging, strengthening Stryker’s position as a leader in surgical guidance.

Through the partnership with Synaptive Medical, Stryker will offer the BrightMatter™ Plan software, which automatically generates high-fidelity, dynamic, whole-brain tractography.  Surgeons can easily review tracts and explore multiple surgical approaches to create powerful pre-operative plans—for every case.  Tractography can be used, without disrupting surgical workflow, to confirm the data is concordant with the intended approach and determine whether detailed surgical planning is required. Then, the surgical plans can be easily exported for navigation in the operating room.

BrightMatter Plan is the only tractography offering that is automated and whole-brain.  Other solutions on the market require a neuroradiologist or other tractography expert to generate tracts, which is both time consuming and a road block for surgeons.

“We are committed to providing our customers with a complete solution for surgical guidance,” said Lisa Kloes, General Manager of Stryker’s Advanced Guidance Technologies business. “The partnerships with Synaptive Medical and Ziehm Imaging are an important step in that direction.”

The Ziehm Vision RFD 3D C-arm, which Stryker will now offer as part of its agreement with Ziehm Imaging, offers the latest flat-panel technology for CT-like image quality, giving surgeons access to detail-rich imaging that provides the accuracy and efficiency required in demanding orthopaedic, trauma or spinal procedures, all with minimized dose and less time.

Over the last several years, Stryker’s Advanced Guidance Technologies’ product and service offerings have evolved beyond the traditional scope of navigation to also include Imaging, Augmented Reality and Planning Software. With the addition of BrightMatter Plan and Ziehm Vision RFD 3D C-arm to its portfolio, Stryker’s Advanced Guidance Technologies reinforces its commitment to providing customers with better and complete surgical guidance solutions.

To learn more about this expanded portfolio, please visit booth #1529 at The Congress of Neurological Surgeons (CNS).

About Stryker
Stryker is one of the world’s leading medical technology companies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in Orthopaedics, Medical, Surgical, Neurotechnology and Spine that help improve patient and hospital outcomes. More information is available at www.stryker.com.

Media contact
Jennifer Lentner 
jennifer.lentner@stryker.com

SOURCE Stryker

Related Links

http://www.stryker.com

Additive Orthopaedics Announces Receipt of NJ CoVest Fund Award

LITTLE SILVER, N.J., Oct. 8, 2018 /PRNewswire/ — Additive Orthopaedics, LLC., the leader in 3D printed orthopaedic foot and ankle devices, today announced it has been approved for the NJ CoVest Fund through the New Jersey Economic Development Authority (EDA). The Fund is designed to help emerging technology companies bridge the funding gap between product development and commercialization.

According to Greg Kowalczyk, President of Additive Orthopaedics, “This is a tremendous honor and opportunity that we are privileged to accept from the State of New Jersey. We are now able to add additional corporate resources to provide even more limb salvage solutions to patients that were previously unavailable.”

EDA Chief Executive Officer Tim Sullivan noted the important role the Fund plays in fostering innovation across the Garden State and furthering the EDA’s ability to support businesses throughout their growth lifecycle.

“Ensuring that pioneering companies like Additive Orthopaedics have access to critical capital between product development and commercialization is a pivotal step in re-establishing New Jersey as a leader in innovation,” Sullivan said. “We are especially pleased that Additive Orthopaedics plans to use the funding from its NJ CoVest loan to expand its workforce.”

Additive Orthopaedics has already seen a growing market need in 2018 for 3D printed orthopaedic complex reconstruction, limb salvage, and revision implants, and will continue to address patient conditions where there are no commercially available devices on the market.

Recent Updates from Additive Orthopaedics, LLC.
Additive Orthopaedics recently became the leading sponsor in the American Society of 3D Printing. Launched in 2017, the mission of the society is to provide an educational forum for surgeons involved in clinical treatments leveraging 3D printing and to support patients in need.

About Additive Orthopaedics, LLC.
Additive Orthopaedics is an early stage orthopaedic company focused on the integration of advanced manufacturing and biologics to improve patient outcomes.

About the NJ CoVest Fund
The NJ CoVest Fund provides funding to New Jersey technology and life sciences companies to further commercialize their technology and scale revenues. Investments made through the NJ CoVest Fund align with the EDA’s ongoing strategy of supporting New Jersey’s entrepreneurial ecosystem.

Contact:
Greg Kowalczyk
732.882.6633
greg@additiveorthopaedics.com

SOURCE Additive Orthopaedics, LLC.

Related Links

http://www.additiveorthopaedics.com

Corin signs binding agreement for the acquisition of Global Orthopaedic Technology

Cirencester, UK Corin, backed by the Permira Funds is pleased to announce the signing of a binding agreement for the acqusition of Global Orthopaedic Technology Pty Ltd (“GOT”), the largest Australian-based orthopaedic implant designer and manufacturer.

The acquisition will strengthen Corin’s position as a global leader in the hip and knee joint replacement market and is a testament to Corin’s accelerated global expansion and focus on innovation. Corin’s R&D Hub in Australia is a key pillar of its global innovation capabilities and differentiated product offering. The combination with GOT provides significant scale to Corin’s operations in Australia – one of the world’s most attractive orthopaedics markets, as well as additional R&D expertise.

Global Orthopaedics Technology formed 19 years ago, offers an extensive range of orthopaedic implants including knee and hip products with enabling robotics and navigation technologies. The company has a significant Australian footprint and an export business in the USA.

Stefano Alfonsi, Chief Executive Officer of Corin, commented, “This agreement will further strengthen our presence in the sophisticated and competitive Australian market. The combination of Corin and GOT capabilities creates a leading player in Australia with stronger ability to fulfill the needs of hip and knee surgeons. I look forward to welcoming the talented GOT team into the Corin global family.”

Andrew Fox-Smith, Chief Executive Officer of GOT said, “Our acquisition by Corin represents a fantastic next step for both our people and our customers. Corin has an excellent track record in the total joint replacement market and their dynamic and innovative culture is a natural fit to how we have been operating over the last 4 years. We’re very excited about what the combined business can achieve, not only here in Australia but also via faster expansion internationally of GOT’s Australian developed product portfolio.”

Silvia Oteri, Partner with Permira, commented, “The Permira funds backed Corin and its outstanding management team as it is a strong and ambitious leader in its market with a clear vision to revolutionise orthopaedics. The GOT acquisition represents an important step forward in building a leading and innovative successful platform in the space.”

Media Enquiries
For Corin
Elvio Gramignano, Global Strategic Marketing Director
+44 (0) 1285 884 725
+44 (0) 7769 883 675
elvio.gramignano@coringroup.com

Vaughan Bonny Managing Director, Australia and New Zealand
+61 (0)2 94977400
Mobile: +61 (0)437 777 121
vaughan.bonny@coringroup.com

For Permira 
James Olley (Montfort Communications)
+44 203 770 7909
jolley@montfort.london

Notes to Editors

About Corin 

Headquartered in Cirencester, UK, Corin is an international orthopaedic company with a direct presence in a majority of the world’s orthopaedic markets and a track record of strong double-digit growth. Corin’s vision is to revolutionise orthopaedics by gaining, understanding and sharing insight at every stage of the arthroplasty experience. The unique combination of shared knowledge and clinically-proven implants delivers better outcomes and maximises healthcare value for patients, surgeons and healthcare providers.

About Global Orthopaedic Technology 
GOT was formed 19 years ago and is the largest Australian-owned orthopaedic implant designer and manufacturer. It has a significant footprint throughout Australia and an export business in the USA, with plans to expand to Asia and Europe. It offers an extensive range of orthopaedic implants including knee and hip products, as well as providing enabling technologies such as robotics and navigation methodologies.

About Permira 
Permira is a global investment firm. Founded in 1985, the firm advises private equity funds with a total committed capital of over €33bn and makes long-term majority and strategic minority investments in companies with the objective of transforming their performance and driving sustainable growth. The Permira funds have made over 250 private equity investments in five key sectors: Consumer, Technology, Industrials, Healthcare and Financial Services.

Permira employs over 200 people in 14 offices across Europe, North America and Asia. For more information please visit www.permira.com.

3D-Printed Implants Successful in Foot and Ankle Surgery

ROSEMONT, IllinoisOct. 5, 2018 /PRNewswire-HISPANIC PR WIRE/ — According to a new study published in Foot & Ankle International (FAI), advancements in three-dimensional (3D) printing have allowed foot and ankle orthopaedic surgeons to use custom-made implants for difficult foot and ankle cases. The implants offer a new approach to treat complex lower extremity pain and deformities.

Researchers at Duke University Department of Orthopaedic Surgery studied 15 patients who received custom 3D-printed titanium implants between 2014 and 2016 to treat poor bone quality, bone loss, and deformity. In each case, the implants were initially developed by obtaining a computed tomography (CT) scan of the patient and uploading the data to a software program that allowed 3D manipulation of the bones and joints. From there, the senior surgeon and company engineers designed and approved the implant. The benefits of 3D-printed implants include unlimited shapes, increased options in size, and less morbidity or complications.

“This is the first case series looking at the use of 3D-printed implants in foot and ankle surgery,” said Samuel B. Adams, MD, director of foot and ankle research at Duke University Medical Center and senior author of the study. “This short-term study is also the first to demonstrate improvement in patient-reported outcomes with the use of 3D-printed implants. The injuries of many of the patients treated in this study would have required an amputation without this technology.”

CT scans showed that the custom 3D-printed titanium implants were successful in 13 of 15 of the patients who took part in the study. The patients with successful outcomes reported significant improvement in pain and stated they would undergo the same procedure again to save their foot or ankle.

The authors of the study suggest that 3D printing could revolutionize medical care, specifically in modeling for medical education and creating custom artificial body parts. The study notes that longer-term follow-up is needed to understand the longevity and potential complications of these 3D-printed implants.

“The future of 3D printing is very bright. Surgeons who may have been skeptical about using this technology can now use this data to make an informed decision about using it to improve patient care,” said Dr. Adams.

The studyUse of Patient-Specific 3D-Printed Titanium Implants for Complex Foot and Ankle Limb Salvage, Deformity Correction, and Arthrodesis Procedures,” appears in the August 2018 issue of Foot & Ankle International, the official journal of the American Orthopaedic Foot & Ankle Society (AOFAS). FAI is published by SAGE Journals. Author conflicts of interest and funding information are provided within the study.

About Foot and Ankle Orthopaedic Surgeons 
Foot and ankle orthopaedic surgeons are medical doctors (MD and DO) who specialize in the diagnosis and treatment of musculoskeletal disorders and injuries of the foot and ankle. Their education and training consists of four years of medical school, five years of postgraduate residency, and a fellowship year of specialized surgical training. These specialists care for patients of all ages, performing reconstructive surgery for deformities and arthritis, treating sports injuries, and managing foot and ankle trauma.

About the AOFAS 
The American Orthopaedic Foot & Ankle Society (AOFAS) mobilizes our dynamic community of foot and ankle orthopaedic surgeons to improve patient care through education, research, and advocacy. As the premier global organization for foot and ankle care, AOFAS delivers exceptional events and resources for continuous education, funds and promotes innovative research, and broadens patient understanding of foot and ankle conditions and treatments. By emphasizing collaboration and excellence, AOFAS inspires ever-increasing levels of professional performance leading to improved patient outcomes. For more information visit the American Orthopaedic Foot & Ankle Society online at aofas.org.

Logo – https://mma.prnewswire.com/media/328804/american_orthopaedic_foot___ankle_society.jpg

SOURCE American Orthopaedic Foot & Ankle Society

Related Links

http://www.aofas.org

K2M Group Holdings, Inc. Announces Record Date and Meeting Date for Special Meeting of Stockholders

LEESBURG, Va., Oct. 05, 2018 (GLOBE NEWSWIRE) — K2M Group Holdings, Inc. (Nasdaq: KTWO) (the “Company” or “K2M”), announced today that it has set a record date and meeting date for a special meeting of its stockholders to, among other things, consider and vote on a proposal to adopt the previously announced Agreement and Plan of Merger, dated as of August 29, 2018, by and among Stryker Corporation (“Stryker”), Austin Merger Sub Corp. (“Merger Sub”) and K2M, pursuant to which, on the terms and subject to the conditions set forth therein, Merger Sub will merge with and into K2M, with K2M surviving the merger as a wholly owned subsidiary of Stryker (the “Merger”). At the special meeting, K2M stockholders will also vote on a non-binding advisory proposal to approve the compensation that will or may become payable to K2M’s named executive officers in connection with the consummation of the Merger.

K2M stockholders of record as of the close of business on Thursday, October 4, 2018 will be entitled to receive notice of the special meeting and to vote at the special meeting.  The special meeting will be held on Wednesday, November 7, 2018 at 8:00 a.m., Eastern Time, at K2M’s headquarters, 600 Hope Parkway SE, Leesburg, VA 20175.

Upon the completion of the Merger, K2M stockholders will be entitled to receive $27.50 in cash, without interest and less any applicable withholding taxes, for each share of common stock, par value $0.001 per share, of K2M that they own as of immediately prior to the effective time of the Merger.  The Merger is expected to close in the fourth quarter of 2018, subject to customary closing conditions, including approval by K2M’s stockholders and the receipt of certain regulatory approvals.

K2M also announced today that it has filed a definitive proxy statement with the U.S. Securities and Exchange Commission on October 5, 2018 with respect to the special meeting.  K2M expects to commence mailing the definitive proxy statement to its stockholders on or about October 9, 2018.

Any stockholder questions about the merger, including how to vote shares of K2M common stock, should be directed to K2M’s proxy solicitor, Broadridge Financial Solutions, Inc. at 51 Mercedes Way, Edgewood, NY 11717, or to K2M at IR@K2M.com.

About K2M Group Holdings, Inc.

K2M Group Holdings, Inc. is a global leader of complex spine and minimally invasive solutions focused on achieving three-dimensional Total Body Balance™. Since its inception, K2M has designed, developed, and commercialized innovative complex spine and minimally invasive spine technologies and techniques used by spine surgeons to treat some of the most complicated spinal pathologies. K2M has leveraged these core competencies into Balance ACS®, a platform of products, services, and research to help surgeons achieve three-dimensional spinal balance across the axial, coronal, and sagittal planes, with the goal of supporting the full continuum of care to facilitate quality patient outcomes. The Balance ACS platform, in combination with the Company’s technologies, techniques and leadership in the 3D-printing of spinal devices, enables K2M to compete favorably in the global spine surgery market. For more information, visit www.K2M.com and connect with us on FacebookTwitterInstagramLinkedIn and YouTube.

Forward-Looking Statements

The foregoing contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. We intend for these forward-looking statements to be covered by the safe harbor provisions of the federal securities laws relating to forward-looking statements. These forward-looking statements include statements relating to the expected timing, completion and effects of the proposed merger, as well as other statements representing management’s beliefs about, future events, transactions, strategies, operations and financial results, including, without limitation, our expectations with respect to the costs and other anticipated financial impacts of the merger; future financial and operating results of K2M Group Holdings, Inc. (“K2M”); K2M’s plans, objectives, expectations and intentions with respect to future operations and services; required approvals to complete the merger by our stockholders and by governmental regulatory authorities, and the timing and conditions for such approvals; the stock price of K2M prior to the consummation of the transactions; and the satisfaction of the closing conditions to the proposed merger. Such forward-looking statements often contain words such as “assume,” “will,” “anticipate,” “believe,” “predict,” “project,” “potential,” “contemplate,” “plan,” “forecast,” “estimate,” “expect,” “intend,” “is targeting,” “may,” “should,” “would,” “could,” “goal,” “seek,” “hope,” “aim,” “continue” and other similar words or expressions or the negative thereof or other variations thereon. Forward-looking statements are made based upon management’s current expectations and beliefs and are not guarantees of future performance. Such forward-looking statements involve numerous assumptions, risks and uncertainties that may cause actual results to differ materially from those expressed or implied in any such statements. Our actual business, financial condition or results of operations may differ materially from those suggested by forward-looking statements as a result of risks and uncertainties which include, among others, those risks and uncertainties described in any of our filings with the Securities and Exchange Commission (the “SEC”). Certain other factors which may impact our business, financial condition or results of operations or which may cause actual results to differ from such forward-looking statements are discussed or included in our periodic reports filed with the SEC and are available on our website at www.K2M.com under “Investor Relations.” You are urged to carefully consider all such factors. Although it is believed that the expectations reflected in such forward-looking statements are reasonable and are expressed in good faith, such expectations may not prove to be correct and persons reading this communication are therefore cautioned not to place undue reliance on these forward-looking statements which speak only to expectations as of the date of this communication. We do not undertake or plan to update or revise forward-looking statements to reflect actual results, changes in plans, assumptions, estimates or projections, or other circumstances occurring after the date of this communication, even if such results, changes or circumstances make it clear that any forward-looking information will not be realized. If we make any future public statements or disclosures which modify or impact any of the forward-looking statements contained in or accompanying this communication, such statements or disclosures will be deemed to modify or supersede such statements in this communication.

Additional Information and Where to Find It

This communication does not constitute an offer to buy or sell or the solicitation of an offer to buy or sell any securities or a solicitation of any vote or approval. This communication relates to a proposed acquisition of K2M by Stryker Corporation. In connection with this proposed acquisition, K2M has filed a definitive proxy statement and has filed or may file other documents with the SEC. This communication is not a substitute for any proxy statement or other document K2M has filed or may file with the SEC in connection with the proposed transaction. INVESTORS AND SECURITY HOLDERS OF K2M ARE URGED TO READ THE PROXY STATEMENT AND OTHER DOCUMENTS THAT HAVE BEEN (OR MAY BE) FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN IMPORTANT INFORMATION. The definitive proxy statement will be mailed to stockholders of K2M on or about October 9, 2018. Investors and security holders may obtain free copies of these documents and other documents filed with the SEC by K2M through the website maintained by the SEC at http://www.sec.gov. Copies of the documents filed with the SEC by K2M are available free of charge on K2M’s internet website at www.K2M.com or upon written request to: Secretary, K2M Group Holdings, Inc., 600 Hope Parkway SE, Leesburg, Virginia 20175, or by telephone at (703) 777-3155.

Participants in Solicitation

K2M, its directors and certain of its executive officers may be considered participants in the solicitation of proxies in connection with the proposed transaction. Information regarding the persons who may, under the rules of the SEC, be deemed participants in such solicitation in connection with the proposed merger is set forth in the definitive proxy statement filed with the SEC on October 5, 2018. Information about the directors and executive officers of K2M is set forth in its Annual Report on Form 10-K for the fiscal year ended December 31, 2017, which was filed with the SEC on March 1, 2018, its proxy statement for its 2018 annual meeting of stockholders, which was filed with the SEC on April 20, 2018, its Quarterly Reports on Form 10-Q for the quarterly periods ended March 31, 2018 and June 30, 2018, which were filed with the SEC on May 2, 2018 and August 2, 2018, respectively, and its Current Reports on Form 8-K or Form 8-K/A, which were filed with the SEC on January 8, 2018, January 9, 2018, February 28, 2018, March 29, 2018, May 1, 2018, June 11, 2018, June 14, 2018, June 18, 2018, August 1, 2018, and August 30, 2018.

These documents can be obtained free of charge from the sources indicated above. Additional information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, is contained in the definitive proxy statement and other relevant materials filed with the SEC.



NuVasive To Showcase Comprehensive Solutions For Complex Spinal Deformities At Scoliosis Research Society Annual Meeting

SAN DIEGOOct. 4, 2018 /PRNewswire/ — NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced it will highlight several of its latest spinal innovations to treat complex spinal deformities at the Scoliosis Research Society (SRS) Annual Meeting held October 10-13, 2018 in Bologna, Italy. As a Double Diamond Sponsor of SRS, NuVasive continues to demonstrate a strong leadership position in offering transformative solutions within the complex adult and pediatric deformity market segments.

“The NuVasive deformity portfolio is one of the most differentiated portfolios in the market offering surgical efficiency, operative reliability and procedural versatility,” said Matt Link, executive vice president, strategy, technology and corporate development for NuVasive. “This latest expansion of the NuVasive deformity portfolio is a further testament of our commitment to building out comprehensive treatment options for both adult and pediatric patients.”

NuVasive’s complex spine technologies are recognized as best-in-class solutions. Since the introduction of the RELINE® posterior fixation portfolio in May 2015, the overall complex fixation business line, defined as cases with more than five levels of spinal correction, has experienced double-digit revenue growth. This validates NuVasive’s solutions are being utilized by more surgeons to help treat some of the most high-risk patients, and the Company continues to look for new opportunities to further invest in this growing market.

During the meeting, NuVasive will demonstrate several of its latest technologies for complex spinal deformities:

  • VersaTie® is a posterior band system designed to provide clinical versatility and flexibility in the treatment of complex spinal pathologies in both adult and pediatric patients. The system provides primary and supplemental fixation options for patients where traditional fixation may not be feasible. VersaTie supports advanced spine translation techniques in adolescent idiopathic scoliosis (AIS) patients by providing controlled, hands-free translation, and will be commercially available at the end of October 2018. For adult deformity patients, VersaTie offers an advanced solution for distributed loading across the fixation hardware. The band system’s independent locking connector and advanced tensioning device offers enhanced control to address the variable needs of spine surgery. VersaTie’s adult application will be commercially available by end-of-year, and feature a unique new band providing increased strength characteristics.
  • RELINE Navigation.S consists of new instrumentation that offers a complete navigation-compatible solution with surgical navigation. Optimal screw placement and pullout resistance are key surgical objectives to building a strong fixation construct in the adult deformity market, and this new system offers surgeons navigation-compatible instrumentation to optimize clinical outcomes during complex cases.
  • RELINE Small Stature (RSS), launched in July 2018, is the first pediatric deformity fixation solution to accept 4.5mm, 4.75mm and 5.0mm rods in a low-profile tulip, combining rod strength with low-profile implants. With RSS, surgeons have the ideal implant profile for young children without compromising on rod strength within the system. The RSS system was built to give surgeons heightened anatomical awareness through the instrumentation, and provide final fusion strength with a 5.0mm Cobalt Chrome rod option for reliable deformity correction. RSS is also compatible with NuVasive’s MAGEC® system to provide a comprehensive solution for the treatment of Early Onset Scoliosis.

NuVasive will also showcase LessRay®, its hardware and software technology that helps reduce radiation exposure in the operating room (OR), which is particularly important when treating pediatric patients. In addition, the Company’s new Pulse™ surgical automation platform will be on display with the Siemens Healthineers’ Cios Spin* advanced mobile 3D-imaging system, creating the industry’s first Spine Precision Partnership™. These integrated systems can be clinically utilized throughout all deformity and degenerative spinal cases, and has the ability to enhance the OR procedural workflow and offer real-time feedback to aid in clinical decision making.

*Cios Spin from Siemens Healthineers is pending 510(k) clearance, and is not yet commercially available in the U.S.

About NuVasive
NuVasive, Inc. (NASDAQ: NUVA) is the leader in spine technology innovation, focused on transforming spine surgery and beyond with minimally disruptive, procedurally integrated solutions designed to deliver reproducible and clinically-proven surgical outcomes. The Company’s portfolio includes access instruments, implantable hardware, biologics, software systems for surgical planning, navigation and imaging solutions, magnetically adjustable implant systems for spine and orthopedics, and intraoperative monitoring service offerings. With over $1 billion in revenues, NuVasive has an approximate 2,400 person workforce in more than 40 countries serving surgeons, hospitals and patients. For more information, please visit www.nuvasive.com.

Forward-Looking Statements
NuVasive cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive’s results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company’s surgical products and procedures by spine surgeons, development and acceptance of new products or product enhancements, clinical and statistical verification of the benefits achieved via the use of NuVasive’s products (including the iGA® platform), the Company’s ability to effectually manage inventory as it continues to release new products, its ability to recruit and retain management and key personnel, and the other risks and uncertainties described in NuVasive’s news releases and periodic filings with the Securities and Exchange Commission. NuVasive’s public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.

SOURCE NuVasive, Inc.

Related Links

http://www.nuvasive.com

Histogenics Corporation Announces Proposed Public Offering of Common Stock and Warrants

WALTHAM, Mass., Oct. 04, 2018 (GLOBE NEWSWIRE) — Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a leader in the development of restorative cell therapies, today announced that it intends to offer and sell shares of its common stock and accompanying warrants to purchase shares of common stock in an underwritten public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.  All of the securities in the offering are to be sold by Histogenics.

Histogenics intends to use the net proceeds from the offering to complete the submission of the NeoCart® biologics license application and prepare for commercialization of NeoCart following approval by the U.S. Food and Drug Administration, if at all, and for general corporate purposes.

Canaccord Genuity LLC and BTIG, LLC are acting as the joint book-running managers for the offering.

A shelf registration statement on Form S-3 (File No. 333-216741) relating to the public offering of the shares of common stock and the accompanying warrants to purchase shares of common stock described above was filed with the Securities and Exchange Commission (the SEC) and declared effective by the SEC on March 30, 2017. A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the offering will be filed with the SEC and made available on the SEC’s web site at www.sec.gov. Copies of the preliminary prospectus supplement and accompanying prospectus relating to the offering, when available, may also be obtained by contacting Canaccord Genuity LLC, 99 High Street, Suite 1200, Boston, MA 02110, Attn: Equity Syndicate Department, by telephone at (617) 371-3900 or by e-mail at prospectus@canaccordgenuity.com, or BTIG, LLC, 825 Third Avenue, 6th Floor, New York, NY, 10022, or by telephone at (212) 593-7555 or by e-mail at equitycapitalmarkets@btig.com.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any of these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted.

About Histogenics Corporation

Histogenics (Nasdaq: HSGX) is a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function.  Histogenics’ lead investigational product, NeoCart, is designed to rebuild a patient’s own knee cartilage to treat pain at the source and potentially prevent a patient’s progression to osteoarthritis.  NeoCart is one of the most rigorously studied restorative cell therapies for orthopedic use.  NeoCart is designed to perform like articular hyaline cartilage at the time of treatment, and as a result, may provide patients with more rapid pain relief and accelerated recovery as compared to the current standard of care. Histogenics’ technology platform has the potential to be used for a broad range of additional restorative cell therapy indications.

Forward-Looking Statements

This press release contains “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995, regarding, among other things, the proposed public offering of Histogenics’ common stock and warrants. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual results to differ materially from those projected in its forward-looking statements. Meaningful factors which could cause actual results to differ, including completion of the proposed public offering on the anticipated terms, or at all, market conditions and the satisfaction of customary closing conditions related to the proposed public offering, as well as other factors, are discussed in the risks and uncertainties detailed from time to time in Histogenics’ filings with the SEC, including without limitation, under Histogenics’ Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Histogenics undertakes no obligation to revise or update these forward-looking statements, whether as a result of new information, future events or otherwise.



Study Demonstrating Globus Medical’s Expandable Technology Improves Lordosis and Reduces Subsidence Awarded Best Paper at SMISS

AUDUBON, Pa., Oct. 04, 2018 (GLOBE NEWSWIRE) — Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, announced today that a recent clinical study evaluating static versus expandable lateral lumbar interbody fusion devices was awarded best paper at the Society for Minimally Invasive Spine Surgery (SMISS) Annual Forum held last month.

The study, led by Dr. Richard Frisch, an orthopedic surgeon at Southeastern Spine Institute, compared clinical and radiographic outcomes of sixty-four patients who underwent minimally invasive lateral lumber interbody fusion (LLIF) for symptomatic degenerative disc disease. At one year postoperative follow up, patients treated with Globus Medical’s expandable technology experienced significantly greater segmental lordosis and a significantly lower subsidence rate than those in the static group, based on radiographic evidence.  Both the expandable and static spacer groups reported similar improvements in back pain scores with no significant differences in clinical outcomes.

“Subsidence of interbody spacers is a clinical concern due to loss of disc height and foraminal height, and the recurrence of symptoms that may result in revision surgery,” said Dr. Frisch. “The preliminary results of this study suggest that expandable lateral interbody spacers offer important clinical advantages by increasing and maintaining segmental lordosis while potentially decreasing the risk of endplate damage and subsidence.”

Andrew Iott, Senior Vice President of Global Product Development, commented, “Globus Medical would like to congratulate Dr. Frisch on receiving this best paper award at SMISS. We are proud to have sponsored this important research demonstrating the benefits of expandable interbody spacers. As the market leader in expandable interbody technologies, Globus is committed to developing next generation implants that provide innovative solutions to maximize lordosis and help address sagittal imbalance.”

To access the study and learn more about Globus Medical’s portfolio of lateral expandable interbody spacers, visit  www.GlobusMedical.com/LLIF

About Globus Medical, Inc.
Globus Medical, Inc. is a leading musculoskeletal solutions company based in Audubon, PA. The company was founded in 2003 by an experienced team of professionals with a shared vision to create products that enable surgeons to promote healing in patients with musculoskeletal disorders. Additional information can be accessed at http://www.globusmedical.com.

Safe Harbor Statements
All statements included in this press release other than statements of historical fact are forward-looking statements and may be identified by their use of words such as “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan” and other similar terms. These forward-looking statements are based on our current assumptions, expectations and estimates of future events and trends. Forward-looking statements are only predictions and are subject to many risks, uncertainties and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted. These risks and uncertainties include, but are not limited to, factors affecting our quarterly results, our ability to manage our growth, our ability to sustain our profitability, demand for our products, our ability to compete successfully (including without limitation our ability to convince surgeons to use our products and our ability to attract and retain sales and other personnel), our ability to rapidly develop and introduce new products, our ability to develop and execute on successful business strategies, our ability to comply with changing laws and regulations that are applicable to our businesses, our ability to safeguard our intellectual property, our success in defending legal proceedings brought against us, trends in the medical device industry, general economic conditions, and other risks. For a discussion of these and other risks, uncertainties and other factors that could affect our results, you should refer to the disclosure contained in our most recent annual report on Form 10-K filed with the Securities and Exchange Commission, including the sections labeled “Risk Factors” and “Cautionary Note Concerning Forward-Looking Statements,” and in our Forms 10-Q, Forms 8-K and other filings with the Securities and Exchange Commission. These documents are available at www.sec.gov. Moreover, we operate in an evolving environment. New risk factors and uncertainties emerge from time to time and it is not possible for us to predict all risk factors and uncertainties, nor can we assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements. Forward-looking statements contained in this press release speak only as of the date of this press release. We undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof.

Contact:
Brian Kearns
Vice President, Business Development and Investor Relations
Phone: (610) 930-1800
Email:  investors@globusmedical.com
www.globusmedical.com